Mizuho Securities analyst Graig Suvannavejh maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report) today and set a price target of $86.00. The company’s shares closed yesterday at $74.29.
According to TipRanks, Suvannavejh is a 4-star analyst with an average return of 5.3% and a 53.73% success rate. Suvannavejh covers the Healthcare sector, focusing on stocks such as Axsome Therapeutics, Bioxcel Therapeutics, and Karuna Therapeutics.
Axsome Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $109.30.
See the top stocks recommended by analysts >>
The company has a one-year high of $82.00 and a one-year low of $20.63. Currently, Axsome Therapeutics has an average volume of 1.27M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Axsome Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies for the management of central nervous system disorders. Its product candidates include AXS-02 and AXS-06 which are developing for multiple indications. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.
Read More on AXSM:
- Axsome Therapeutics management to meet with Truist
- Axsome Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on February 27
- Axsome Therapeutics price target raised to $86 from $80 at Mizuho
- Axsome Therapeutics initiated with a Neutral at Piper Sandler
- Axsome Therapeutics named Top Pick for first half of 2023 at BTIG
